Intel stock extends gains after report of possible U.S. government stake
Investing.com - Baird has raised its price target on Editas Medicine (NASDAQ:EDIT) to $6.00 from $4.00 while maintaining an Outperform rating on the stock. The new target represents the highest among analysts, whose price targets range from $1.00 to $6.00. According to InvestingPro data, the stock has surged over 86% in the past six months.
The price target increase follows Editas Medicine’s second-quarter 2025 earnings and pipeline updates, which Baird noted were generally in line with expectations.
Editas management continues to work on advancing the company’s in vivo editing programs, according to Baird’s analysis of the quarterly results.
Baird highlighted that the anticipated announcement of a lead candidate in September could potentially spark investor interest in Editas.
The research firm specifically noted Editas’ strategic focus on prioritizing opportunities where in vivo gene editing will drive unique biologic effects, rather than pursuing "me too" applications that characterized previous knockdown programs.
In other recent news, Editas Medicine, Inc. has announced significant advancements in liver disease treatment with promising results from an in vivo CRISPR study. The study demonstrated a substantial reduction in disease-specific biomarkers in mice, achieving approximately 70% editing efficiency. In parallel developments, Editas Medicine amended its 2015 Stock Incentive Plan, extending its term and updating its provisions to align with current legal and accounting standards. Additionally, Evercore ISI has adjusted its price target for Editas Medicine, lowering it to $4 while maintaining an Outperform rating, noting the company’s cash reserves are expected to support operations until the second quarter of 2027.
Meanwhile, NuCana plc has released its 2024 UK Annual Report, detailing the company’s financial performance and strategic initiatives over the past year. The company also announced its Annual General Meeting scheduled for June 27, 2025. These updates were disclosed in a recent SEC filing, offering shareholders insights into the company’s operations. These developments highlight the ongoing activities and financial strategies of both companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.